424B5 filed Sep 4, 2026 at 16:00 ET
Indaptus Therapeutics filed Amendment No. 1 to its August 31, 2026 prospectus supplement, correcting a clerical error in the dilution calculation for its up-to-$100M at-the-market (ATM) offering through H.C. Wainwright. No shares have been sold under the ATM to date. The company has no active clinical programs, discontinued its lead candidate Decoy20, and faces a going-concern risk. The ATM creates massive potential dilution (up to 87.7M shares at $1.14/share, representing ~66% of current outstanding shares), compounding the existing overhang from two prior S-3 resale registrations.